SNT
Syntara Limited
🇦🇺 ASX
🕊️ SOCIALLY AWARE
📦 LOGISTICS
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
-16.95%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
6
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Syntara Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. The company has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.
📈 Performance
Price History
-42.86%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🍃 Environmental, Social and Governance scores ℹ️
🌳
Environmental Score
64
A measure of an organisations or investment's impact on the natural environment, including factors such as carbon emissions, resource usage, and pollution
⚖️
Governance Score
32
An evaluation of an organisations impact on society, focusing on factors such as employee welfare, diversity and inclusion, community engagement, and product safety and quality.
🤓 Advanced information
Technical Info
💰 Price*
$0.03
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in SNT
6
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
11 weeks
💵 Average investment amount
$1,017
⏰ Last time a customer invested in SNT
45 days
SNT investor breakdown
💵 Income of investors
More than 200k
150k - 200k
29%
100k - 150k
43%
50k - 100k
29%
Less than 50k
👶 Age of investors
18 - 25
26 - 34
17%
35 - 90
83%
🙋 Legal gender of investors
Female
33%
Male
67%
Pearlers who invest in SNT also invest in...
Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the business of researching and developing dermatology and antimicrobial products. The company is headquartered in Leederville, Western Australia. The firm is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. The company also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.
🙌 Performance (5Yr p.a)
13.19%
📊 Share price
$0.39 AUD
📦 LOGISTICS
📈 HIGH PRICE GROWTH
Peninsula Energy Ltd. engages in the mining, exploration, and development of uranium properties. The company is headquartered in Subiaco, Western Australia. The firm owns the Lance Project (Lance) and Dagger Project. The Lance Project is located in Wyoming, United States of America, operated through its 100% owned subsidiary, Strata Energy Inc (Strata). The Lance Projects comprise the Ross Production Project Area, Kendrick Development Project Area and Barber Exploration Area. The Lance Projects are located in Crook County, in northeastern Wyoming, approximately 31 miles east-northeast of the town of Gillette and extend over a strike length of 37 kilometers (kms) to the north, and over a strike width of eight km. The company holds mineral rights and surface access rights over a non-contiguous north-south distance of about 50 km. The company has mineral rights over 34,068 acres and surface access rights over land holdings 8,426 acres. The Dagger Project in Crook County, Wyoming lies within the North Black Hills district in the northeast corner of the state.
🙌 Performance (5Yr p.a)
-8.87%
📊 Share price
$0.09 AUD
⚡️ ENERGY
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.
🙌 Performance (5Yr p.a)
115.62%
📊 Share price
$13.46 AUD
📦 LOGISTICS
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
17.56%
📊 Share price
$55.75 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
Fortescue Ltd. engages in the development of iron ore deposits. The company is headquartered in Perth, Western Australia. The firm operates through two segments: Metals, and Energy. The Metals segment is engaged in the exploration, development, production, processing, sale and transportation of iron ore, and the exploration for other minerals. The Energy segment is engaged in the development of green electricity, green hydrogen, and green ammonia projects. Through its growth project Iron Bridge and its interest in the Belinga Iron Ore Project in Gabon, it is investing in the growth of its iron ore business. Its integrated operations in the Pilbara include the Chichester, Solomon and Western mining hubs. Its mining infrastructure is connected to the five berth Herb Elliott Port and Judith Street Harbour towage facility in Port Hedland. The Solomon Hub in the Hamersley Ranges is located 60 kilometers (km) north of Tom Price and 120km to the west of the Chichester Hub.
🙌 Performance (5Yr p.a)
19.55%
📊 Share price
$17.64 AUD
🌳 ENVIRONMENTAL
🕊️ SOCIALLY AWARE
⛏️ MINING
📈 HIGH PRICE GROWTH
Want more shares? Try these...
Sierra Nevada Gold, Inc. engages in the generation and development of mineral exploration projects. The company is headquartered in Reno, Nevada. The company went IPO on 2022-05-03. The firm is exploring five controlled projects, comprising of four gold and silver projects and a large copper/gold porphyry project. Its projects include Blackhawk, Colorback, Warrior, New Pass, and Generative. The Blackhawk Project is located within the Excelsior Mountain Range, Mineral County, Nevada and consists of approximately 636 contiguous 20-acre claims covering 49 square kilometer (km2). The Blackhawk Project occurs within the prolific Walker Lane Trend that hosts gold, copper, and silver deposits. The Colorback Project is in the northwest Battle Mountain Trend of central Nevada and is prospective for giant Carlin style gold deposits. The Colorback Project is located 10 kms southwest of the township of Crescent Valley and consists of approximately 42 contiguous 20-acre claims and covers an area of over 3.4 km2.
📊 Share price
$0.05 AUD
⛏️ MINING
Summerset Group Holdings Ltd. engages in the development and operation of retirement villages and aged care facilities. The firm is engaged in the design, construction, and operation of retirement villages and care centers. The company provides a range of living options and care services to over 8,000 residents. The company offers a choice of independent living options, including villas, townhouses, and serviced apartments. The company offers various facilities in its village, such as recreational bowling green, barbecue facilities, cafe, communal vegetable gardens, courtesy van, exercise room, hair salon, library, organized outings, and activities, piano, pool table, residents' bar, residents' workshop, swimming pool, and spa. The company has approximately 38 villages completed or in development in Aotea, Avonhead, Bell Block, Blenheim, Cambridge, Casebrook, Cranbourne North, Dunedin, Ellerslie, and others. Its portfolio covers over 7,371 total units, including 6,087 retirement units and 1,284 care units.
🙌 Performance (5Yr p.a)
15.94%
📊 Share price
$10.62 AUD
📈 HIGH PRICE GROWTH
🩺 HEALTH CARE
Supply Network Ltd. engages in the provision of after market parts to the commercial vehicle industry. The company is headquartered in Sydney, New South Wales. The firm operates trading entities in Australia and New Zealand under the Multispares brand. Each trading entity has its own management team and its own operating focus within a market definition of replacement parts for road transport equipment. The company sells truck and bus parts. The company also sells a range of services, including parts interpreting, procurement, supply management and problem-solving.
🙌 Performance (5Yr p.a)
122.57%
📊 Share price
$29.37 AUD
🔨 COMMERCIAL SERVICES & SUPPLIES
SenSen Networks Ltd. engages in the development, commercialization, and supply of data-driven business process enhancement solutions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-05-31. The principal activities of the Company include developing and selling SenDISA platform-based products and services into smart city and retail markets across three market segments: Smart Cities, Casinos, and Retail. Smart Cities include civic compliance, traffic data and law enforcement solutions to city councils, national parks, road authorities and transit agencies across the globe. Casinos include delivering actionable insights about casino table game occupancy, hands per hour, bet type and value for every bet placed on the gaming floor. Retail provides anti-theft and debt recovery services to fuel retailers. The Company’s geographical segments include Australia and New Zealand, North America (comprising USA and Canada), and Asia. SenDISA’s Live Awareness automates processes and ensures other decisions can be made more quickly and accurately.
🙌 Performance (5Yr p.a)
-11.82%
📊 Share price
$0.04 AUD
🤖 TECHNOLOGY
🕊️
Social Score
92
An assessment of an organisations management practices, board structure, transparency, and accountability, reflecting its commitment to ethical behavior and responsible decision-making.